Pulmonary Fibrosis Treatments: Cellcept (Mycophenolate Mofetil)

LUNG (PULMONARY): MAIN MENU

Pulmonary Fibrosis

This page was written by Shelley Ensz, and has not yet been medically edited. See Disclaimer.

Overview of Pulmonary Fibrosis
Mortality and Prognosis
Symptoms

Disease Correlations
Diagnosis
Living with Pulmonary Fibrosis

Treatments
Research

Patient Stories
References

Pulmonary Fibrosis Treatments: Cellcept

Overview of Treatments
Antihistamine Warning
Cyclophosphamide (Cytoxan)

Biologic Agents
Mycophenolate Mofetil (Cellcept)

Lung Transplant
Clinical Trials

Oxygen Therapy
Research on New Treatments

Mycophenolate Mofetil (Cellcept)

Scleroderma Lung Study II. This study compares 2 different medications—daily oral cyclophosphamide (CYC, also called CytoxanTM) with daily oral mycophenolate mofetil (MMF, also called CellceptTM) in the treatment of scleroderma-related pulmonary fibrosis. There are twelve study centers across the U.S. This study is currently recruiting. University of California, Los Angeles. November 2009. (Also see: Pulmonary Fibrosis, Cytoxan, and Clinical Trials)

Mycophenolate Mofetil (MMF or Cellcept) in Systemic Sclerosis Associated Interstitial Lung Disease (ILD). There was a significant increase in forced vital capacity (FVC) and a non-significant increase in carbon monoxide diffusing capacity (DLCO) at 12 months in patients on MMF. A. Koutroumpas. (FRI0331) EULAR 2009. (Also see: Cellcept)

Experience of Mycophenolate Mofetil (MMF) in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects. MMF is safe, well tolerated, and allows reduction or discontinuation of prednisone without worsening of symptoms or objective progression of disease. L. A, Saketkoo, MD American Journal of the Medical Sciences. 337(5):329-335, May 2009. (Also see: Cellcept)

Effect of Mycophenolate Mofetil (MMF) on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD). These retrospective data suggest MMF improves vital capacity (VC) in patients with SSc-ILD. Gerbino AJ, Goss CH, Molitor JA. (PubMed) Chest. 2007 Dec 10. (Also see: Cellcept)

Pulmonary Fibrosis In Systemic Sclerosis (SSc) And Dermatomyositis (DM) Demonstrates Marked Improvement After Administration Of Mycophenolate Mofetil (MMF/Cellcept). MMF's immunomodulatory and inhibitory effects on fibroblasts and other non-immune cells and a well established low side effect profile with high tolerance make MMF a potential alternative to cyclophosphamide in the treatment of SSc or DM related interstitial lung disease. L. A. Saketkoo THU0315 EULAR 2007. (Also see: Dermatomyositis)

Mycophenolate mofetil (Cellcept) is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related (CTD) Interstitial lung disease (ILD). Glucocorticoids and immunomodulatory agents are regarded as mainstays of therapy for CTD-related ILD; however, apart from those studies that have evaluated certain medications for patients with scleroderma, few studies have been performed. PubMed. Chest. 2006 Jul;130(1):30-6. (Also see: Medications)

Mycophenolate mofetil (Cellcept) as first-line treatment improves clinically evident early scleroderma lung disease. Our preliminary data suggest that in patients with dSSc and recent, clinically apparent alveolitis, early treatment with Cellcept and small doses of corticosteroids may represent an effective, well-tolerated and safe alternative therapy. PubMed. Rheumatology (Oxford). 2006 Feb 20. (Also see: Medications)